Elidel: Advanced Topical Treatment for Atopic Dermatitis Relief
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 1 | $43.00 | $43.00 (0%) | 🛒 Add to cart |
| 2 | $38.70 | $86.00 $77.40 (10%) | 🛒 Add to cart |
| 3 | $34.40 | $129.00 $103.20 (20%) | 🛒 Add to cart |
| 4 | $32.25 | $172.00 $129.00 (25%) | 🛒 Add to cart |
| 5 | $29.24 | $215.00 $146.20 (32%) | 🛒 Add to cart |
| 6 | $25.80 | $258.00 $154.80 (40%) | 🛒 Add to cart |
| 7 | $23.34 | $301.00 $163.40 (46%) | 🛒 Add to cart |
| 8 | $21.50 | $344.00 $172.00 (50%) | 🛒 Add to cart |
| 9 | $20.07 | $387.00 $180.60 (53%) | 🛒 Add to cart |
| 10 | $18.92
Best per tube | $430.00 $189.20 (56%) | 🛒 Add to cart |
Synonyms | |||
Elidel (pimecrolimus) cream 1% is a non-steroidal topical immunomodulator specifically formulated for the short-term and intermittent long-term treatment of mild to moderate atopic dermatitis (eczema) in non-immunocompromised patients aged 2 years and older. This prescription medication works by selectively inhibiting T-cell activation and cytokine production, targeting the underlying inflammatory pathways responsible for eczema flare-ups without causing the skin thinning and other systemic effects associated with topical corticosteroids. Clinical studies demonstrate that Elidel effectively reduces itching, redness, and scaling while helping to maintain periods of remission between episodes. Its non-steroidal mechanism makes it particularly valuable for sensitive skin areas and patients requiring prolonged therapy.
Features
- Contains pimecrolimus 10 mg/g (1%) as the active pharmaceutical ingredient
- White, homogeneous cream formulation for easy application
- Available in 30g, 60g, and 100g tubes
- Oil-in-water emulsion base with minimal ingredient profile
- pH-balanced formulation (approximately 6.0-7.0)
- Non-comedogenic and fragrance-free
- Stable at room temperature without special handling requirements
Benefits
- Provides rapid relief from itching and inflammation within days of initiation
- Reduces eczema flare frequency and severity when used at first signs
- Preserves skin integrity without causing atrophy, striae, or telangiectasia
- Suitable for application on face, neck, and other sensitive areas
- Enables long-term management with intermittent dosing
- Minimizes need for topical corticosteroids and their associated side effects
Common use
Elidel is primarily indicated for the treatment of mild to moderate atopic dermatitis in patients who:
- Have not responded adequately to other prescription topical treatments
- Cannot tolerate conventional therapies due to side effects
- Require treatment for sensitive skin areas (face, eyelids, neck, skin folds)
- Need intermittent long-term therapy to maintain disease control
- Experience corticosteroid-induced skin changes requiring alternative treatment
The medication is typically applied at the earliest signs or symptoms of eczema flare-ups to prevent full progression of lesions. Clinical studies support its use twice daily until symptoms resolve, which generally occurs within approximately 8 days for facial lesions and 22 days for body lesions in responsive patients.
Dosage and direction
Apply a thin layer of Elidel cream twice daily to affected areas. Gently rub in the cream until it disappears into the skin. Use the smallest amount needed to control signs and symptoms.
Pediatric patients (2-17 years): Apply twice daily to affected areas. Treatment should begin at first signs of itching and redness. Continue use until symptoms clear, then discontinue. May resume treatment at next occurrence of symptoms.
Adults: Apply twice daily to affected areas. Treatment should be initiated at earliest signs of itching and inflammation. Continue application until symptoms resolve.
Important administration notes:
- Do not cover treated areas with occlusive dressings unless medically directed
- Wash hands after application if hands are not being treated
- May be used on any skin surface, including face, neck, and intertriginous areas
- Treatment should be discontinued if resolution occurs, if no improvement is seen after 6 weeks, or if disease worsens
Precautions
- For external use only; avoid contact with eyes and mucous membranes
- Not recommended for use in patients with Netherton’s syndrome or other skin barrier defects
- May cause application site reactions including burning, warmth, or stinging
- Minimize exposure to natural and artificial sunlight (tanning beds, UV lamps) during treatment
- Wear protective clothing and use broad-spectrum sunscreen when outdoors
- Use only as prescribed; do not apply to active cutaneous infections
- Not for use in children under 2 years of age
- Long-term safety beyond 1 year of intermittent use has not been established
Contraindications
- Hypersensitivity to pimecrolimus or any component of the formulation
- Patients with active cutaneous viral infections (herpes simplex, varicella zoster)
- Immunocompromised patients, including those with HIV, lymphoma, or receiving immunosuppressive therapy
- Treatment of clinically infected atopic dermatitis without concomitant anti-infective therapy
- Use in patients with pre-malignant or malignant skin conditions
- Application to areas with potential malignant conditions
Possible side effects
Very common (≥10%):
- Application site burning (most frequent in early treatment, typically mild and transient)
- Application site irritation
Common (1-10%):
- Application site pruritus
- Skin infection (impetigo, folliculitis, herpes simplex)
- Headache
- Increased cough
- Common cold symptoms
- Fever
Uncommon (0.1-1%):
- Skin papilloma
- Alcohol intolerance (facial flushing or skin irritation)
- Lymphadenopathy
- Conjunctivitis
- Eyelid irritation
Rare (<0.1%):
- Anaphylactoid reactions
- Skin discoloration
- Photosensitivity reactions
- Rosacea-like eruptions
Drug interaction
- No formal drug interaction studies have been conducted with Elidel
- Theoretical interactions with other immunosuppressive agents
- Potential increased systemic exposure when used with CYP3A4 inhibitors
- No known interactions with vaccines; however, avoid application to recently vaccinated skin areas
- Caution with concomitant use of other topical medications due to potential increased absorption
Missed dose
If a dose is missed, apply the cream as soon as remembered. However, if it is almost time for the next application, skip the missed dose and resume the regular dosing schedule. Do not apply extra cream to make up for a missed dose.
Overdose
Topical overdose is unlikely due to minimal systemic absorption. However, excessive application may increase the risk of adverse effects. If accidental ingestion occurs, seek medical attention immediately. Symptoms of oral overdose may include headache, nausea, and vomiting. No specific antidote exists; treatment should be symptomatic and supportive.
Storage
- Store at room temperature between 15°C to 30°C (59°F to 86°F)
- Do not freeze
- Keep tube tightly closed when not in use
- Keep out of reach of children and pets
- Do not use after expiration date printed on packaging
- Discard any cream that has changed color or consistency
Disclaimer
This information is provided for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment recommendations. Individual results may vary. The safety and effectiveness of Elidel in children under 2 years of age have not been established. Long-term effects of continuous use beyond 1 year are not known. Patients should be monitored for lymph node enlargement and skin malignancies during treatment.
Reviews
Clinical studies demonstrate: In controlled trials involving over 2000 patients, Elidel showed significant improvement in eczema symptoms compared to vehicle. 51-61% of patients achieved clear or almost clear skin after 6 weeks of treatment versus 19-34% with vehicle alone. Pediatric studies showed similar efficacy with 54.5% of patients achieving treatment success compared to 23.9% with vehicle.
Patient-reported outcomes: 78% of parents reported satisfaction with Elidel treatment in managing their children’s eczema. 72% of adult patients reported improvement in quality of life measures including sleep quality and daily activities.
Dermatologist assessments: 85% of prescribing dermatologists rate Elidel as effective or very effective for facial and neck eczema. 79% report patient satisfaction with the rapid relief of itching and inflammation.
Safety profile: Clinical trials involving over 19,000 patients demonstrate a favorable safety profile with most adverse events being mild to moderate application site reactions that typically resolve within the first few days of treatment.